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A B S T R A C T   
Multiple sclerosis (MS) patients have been considered a higher-risk population for COVID-19 due to the high 
prevalence of disability and disease-modifying therapy use; however, there is little data identifying clinical 
characteristics of MS associated with worse COVID-19 outcomes. Therefore, we conducted a multicenter pro-
spective cohort study looking at the outcomes of 40 MS patients with confirmed COVID-19. Severity of COVID- 
19 infection was based on hospital course, where a mild course was defined as the patient not requiring hospital 
admission, moderate severity was defined as the patient requiring hospital admission to the general floor, and 
most severe was defined as requiring intensive care unit admission and/or death. 19/40(47.5%) had mild 
courses, 15/40(37.5%) had moderate courses, and 6/40(15%) had severe courses. Patients with moderate and 
severe courses were significantly older than those with a mild course (57[50–63] years old and 66[58.8–69.5] 
years old vs 48[40–51.5] years old, P = 0.0121, P = 0.0373). There was differing prevalence of progressive MS 
phenotype in those with more severe courses (severe:2/6[33.3%]primary-progressing and 0/6[0%]secondary- 
progressing, moderate:1/14[7.14%] and 5/14[35.7%] vs mild:0/19[0%] and 1/19[5.26%], P = 0.0075, 1 
unknown). Significant disability was found in 1/19(5.26%) mild course-patients, but was in 9/15(60%, 
P = 0.00435) of moderate course-patients and 2/6(33.3%, P = 0.200) of severe course-patients. Disease- 
modifying therapy prevalence did not differ among courses (mild:17/19[89.5%], moderate:12/15[80%] and 
severe:3/6[50%], P = 0.123). MS patients with more severe COVID-19 courses tended to be older, were more 
likely to suffer from progressive phenotype, and had a higher degree of disability. However, disease-modifying 
therapy use was not different among courses.   
1. Introduction 
Patients with multiple sclerosis (MS) are four times more likely to 
succumb to serious infection when compared to the general population, 
thus making them potentially at higher-risk from the ongoing novel 
coronavirus disease (COVID-19) [1]. This may be because a significant 
number of MS patients have a high level of disability and are on im-
munosuppressive disease-modifying therapies (DMTs). Most informa-
tion regarding the association of MS characteristics and DMT-usage 
with COVID-19 comes from case-reports and case-series surveys [2–4]. 
In this prospective cohort study we assessed the MS disease 
characteristics with differing COVID-19 infection severity. 
2. Methods 
2.1. Study design 
We enrolled 40 consecutive MS patients with confirmed COVID-19 
via nasopharyngeal/oropharyngeal-PCR from 3 different hospital sys-
tems in the U.S, Henry Ford Health Systems (HFHS) in Detroit, MI, 
Detroit Medical Center (DMC) in Detroit MI, and University of Chicago 
(UOC) in Chicago, IL (28 at HFHS, 4 at DMC and 8 at UOC) between 
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Table 1 
Patient characteristics.         
All Mild Moderate Severe P-value  
n 40 19 15 6     
a) Demographics and MS characteristics   
Age in years (IQR) 52 (45.5–61) 48 (40–51.5) 57 (50–63)⁎ 66 (58.8–69.5)⁎ 0.0013 
African American 21/40 (52.5%) 7/19 (36.8%) 9/15 (60%) 5/6 (83.3%) 0.102 
Male 16/40 (40%) 5/19 (26.3%) 8/15 (53.3%) 3/6 (50%) 0.258 
BMI (IQR) 30.6 (25.5–35.9) 30.7 (27–36.4) 28.4 (23.1–33.8) 36.1(34.2–38.8) 0.142 
Smoker 6/39 (15.4%) 1 not specified 0/19 (0%) 5/14 (35.7%)⁎ 1/6 (16.7%) 0.0145 
Phenotype of MS      
PPMS 3/39 (7.69%), 1 not specified 0/19 (0%) 1/14 (7.1%)⁎ 2/6 (33.3%) 0.0075 
RRMS 30/39 (76.9%) 18/19 (94.7%) 8/14 (57.1%)⁎ 4/6 (66.7%)  
SPMS 6/39 (15.4%) 1/19 (5.26%) 5/14 (35.7%)⁎ 0/6 (0%)  
Years with MS(IQR) 12 (6.5–19) 11 (6–14.5) 16 (11.5–27)⁎ 5 (3−10)^ 0.0166 
EDSS ≥6.0 11/37 (29.7%), 3 not specified 1/18 (5.6%) 8/14 (57/1%)⁎ 2/5 (40%) 0.0045 
On DMT 32/40 (80%) 17/19 (89.5%) 12/15 (80%) 3/6(50%) 0.123 
Nursing Home 8/40 (20%) 0/19 (0%) 7/15 (46.7%)⁎ 1/6 (16.7%) 0.0015 
Healthcare Worker 6/40 (15%) 5/19 (26.3%) 1/15 (6.67%) 0/6 (0%) 0.132 
Baseline Absolute Lymphocyte 
Count(IQR) 
1.6 (0.9–1.8), 19 labs not obtained 1.7 (1.35–1.72),  
n = 4 
1.4(0.925–1.85), n = 14 1.6(1.2–2.8),n = 3 0.908    
b) Comorbidities   
Hypertension 16/40 (40%) 3/19 (15.8%) 10/15 (66.7%)⁎ 3/6 (50%) 0.0085 
Hyperlipidemia 7/40 (17.5%) 1/19 (5.26%) 4/15 (26.7%) 2/6 (33.3%) 0.172 
Diabetes 9/40(22.5%) 1/19 (5.26%) 4/15 (26.7%) 4/6 (66.7%)⁎ 0.005 
Asthma/COPD 2/40 (5%) 0/19 (0%) 1/15 (6.67%) 1/6 (16.7%) 0.277    
c) Presentation   
Fever 26/40 (65%) 10/19 (52.6%) 11/15 (73.3%) 5/6 (83.3%) 0.331 
Cough 26/40 (65%) 16/19 (84.2%) 6/15 (40%)⁎ 4/6 (66.7%) 0.0275 
Myalgia 14/40 (35%) 9/19 (47.4%) 3/15 (20%) 2/6 (33.3%) 0.302 
Shortness of Breath 20/40 (50%) 7/19 (36.8%) 8/15 (53.3%) 5/6 (83.3%) 0.148 
Diarrhea 4/40 (10%) 1/19 (5.26%) 3/15 (20%) 0/6 (0%) 0.275 
Sore Throat 4/40 (10%) 3/19 (15.8%) 0/15 (0%) 1/6 (16.7%) 0.366 
Headache 7/40 (17.5%) 3/19 (15.8%) 4/15 (26.7%) 0/6 (0%) 0.42 
Altered Mental Status 4/40 (10%) 0/19 (0%) 4/15 (26.7%) 0/6 (0%) 0.0185 
Require Chest X-Ray 23/40(57.5%) 2/19(10.5%) 15/15(100%)⁎ 6/6(100%)⁎ 0.0005 
Chest X-Ray Abnormality 17/23 (73.9%) 2/2 (100%) 9/15 (60%) 6/6 (100%) 0.132 
Elevated Troponin 3/17 (17.7%), 23 labs not obtained 0/1 (0%) 2/12 (16.7%) ¼ (25%) 0.371 
Elevated LDH; median(IQR) IU/L 15/16 (93.8%), 24 labs not obtained; 
357(254–433) 
0/0 11/12 (91.7%); 
312(245–394) 
4/4 (100%); 598 (402–807) 0.0452 
Elevated Procalcitonin; median 
(IQR) ng/mL 
9/13 (69.2%), 27 labs not obtained; 0.31 
(0.02–0.57) 





Elevated Ferritin; median(IQR) 
ng/mL 
11/16 (75%), 24 labs not 
obtained;703.5(288–1107) 
0/0 8/12 (66.7%); 494 
(195–1030) 
3/4 (75%); 980 (675–1218) 0.332 
Elevated D-Dimer; median (IQR) 
ug/mL 
14/16 (87.5%), 24 labs not obtained; 2.14 
(0.988–3.32) 
0/0 9/11 (81.8%); 2.15 
(0.985–2.84) 
5/5 (100%); 2.13 (1.91–5.5) 0.461 
Elevated CRP; median (IQR) 
mg/dL 
16/16 (100%) 24 labs not obtained: 9 (5–13) 0/0 12/12 (100%); 9 (4–13) 4/4 (100%); 9.5 (7.25–12) 0.734 
Elevated CPK; median (IQR) IU/L 8/15 (53.3%), 25 labs not obtained; 290 
(85–442.5) 
0/0 5/11 (45.5%); 94 (79.5–442) 3/4 (75%); 308 (238–3296) 0.514 
Elevated LFT; median (IQR) IU/L 10/20 (50%), 20 labs not obtained; 24.5 
(19.5–40.8) ALT, 30 (22.75–49.3) AST 
0/1 (100%);21ALT, 
17AST 
8/14 (57.1%); 24 (18.5–37) 
ALT, 34 (24.5–48) AST 
2/5 (40%); 32 (25–70) 
ALT,28 (22−121) AST 
0.638 
White Blood Cell Count (IQR) K/uL 6.5 (5.20–8.3), 19 labs not obtained 4.3, n = 1 5.6 (5.2–9.35), n = 15 7.8 (7.1–8.2), n = 5 0.352 
Neutrophil%(IQR) 79 (65–86), 19 labs not obtained 52, n = 1 79 (64.5–85.5), n = 15 83 (80–88), n = 5 0.163 
Lymphocyte%(IQR) 12 (9–15), 19 labs not obtained 38, n = 1 12 (9–18), n = 15 13 (7–14), n = 5 0.313    
d) Treatment specifically for COVID-19   
Given Treatment 21/40 (52.5%) 4/19 (21.1%) 12/15 (80%)⁎ 5/6 (83.3%)⁎ 0.001 
Hydroxychloroquine 14/40 (35%) 1/19 (5.26%) 8/15 (53.3%)⁎ 5/6 (83.3%)⁎ 0.001 
Antibiotic 13/40 (32.5%) 3/19 (15.8%) 6/15 (40%) 4/6 (66.7%) 0.048 
Methylprednisone 10/40 (25%%) 0/19 (0%) 6/15 (40%)⁎ 4/6 (66.7%)⁎ 0.002    
e) Outcome   
Days Admitted(IQR) 8 (4–14) NA 4 (4–9.5) 15.5 (14.2–16.8) 0.006 
Days with COVID-19 Symptoms 
(IQR) 
16 (13–20.3) 16 (14–21) 14 (4–18.5) 16.5 (14.2–21.8) 0.304 
Require Ventilator 4/40 (10%) NA NA 4/6 (66.7%)  
Death 4/40 (10%) NA NA 4/6 (66.7%)  
Characteristics of all patients. a) Patient demographic data, b) Comorbidities, c) Initial presentation, d) Treatment, e) Outcomes. DMT = Disease Modifying Therapies 
(Details on MS drugs shown in Table 2), PPMS=Primary progressive MS, RRMS = Relapse-remitting MS, SPMS=Secondary progressive MS. EDSS = Expanded 
Disability Status Scale. BMI = Body Mass Index. All continuous variables are expressed with median and interquartile range as median (IQR). All frequencies are 
presented as fraction of counts over number of available counts (Percentage). Lab data is expressed as frequency of elevated labs (%); median (IQR).(Reference values 
shown in Supplementary Table 1) Lactate Dehydrogenase(LDH), C-reactive protein (CRP), Creatine Phosphokinase (CPK), Liver Function Test (LFT). 
⁎ Statistically significant difference compared with mild course. 
^ Statistically significant difference compared with moderate course.  
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March 1st and May 18th. Study was approved by each institution re-
view board (IRB). 
2.2. Data collection 
We obtained information regarding age, race, sex, smoking status, 
MS phenotype (Primary Progressive MS, PPMS; Relapsing-Remitting 
MS, RRMS; Secondary Progressive MS, SPMS), duration of MS, DMT, 
and comorbidities. Expanded disability status scale (EDSS) from last 
clinic visit was used for disability assessment with ≥6.0 indicating 
severe disability [5,6]. Symptoms of infection and laboratory data at 
presentation were also included in the analysis. Days of COVID-19 
symptoms was a patient-reported metric. 
2.3. Outcome measured 
Clinical severity of COVID-19 was based on hospital course: mild 
course was defined as not requiring hospital admission, moderate 
course was defined as requiring admission to general floor only, and 
severe course was defined as requiring intensive care unit (ICU) ad-
mission and/or death [7]. 
2.4. Statistical analysis 
R-version 3.6.3 was used for statistical analysis. Continuous vari-
ables were reported as median with interquartile ranges (median 
[IQR]). Categorical variables were reported as counts (percentages). 
Lab data was expressed as frequency of elevated labs using cut off va-
lues (Supplement Table 1) and median [IQR]. Continuous variables 
were compared using Kruskal-Wallis-H test with post hoc Dunn's test for 
pairwise-comparisons. Due to small sample size, proportions of cate-
gorical variables were compared using Chi-squared test with Monte- 
Carlo simulation with 2000 replicates [8]. Then Fisher multiple-pair-
wise tests were used for post hoc comparisons with Benjamini-Hoch-
berg adjustments [9]. Differences among COVID-19 courses and pair- 
wise comparisons were considered statistically significant if P-value or 
adjusted P-value were less than 0.05. 
3. Results 
3.1. Overall outcomes 
20/40 (50%) patients were admitted, of which 5/20 (25%) patients 
required ICU admission. Of the 20 patients admitted, 4/20 (20%) were 
ventilated and 3/20 (15%) died. One patient died on arrival at the 
emergency department. Therefore, a total of 4/40 (10%) patients died, 
while all other patients recovered (36/40 [90%]). 
3.2. Demographics 
19/40 (47.5%) had mild courses, 15/40 (37.5%) had moderate 
courses, and 6 (15%) had severe courses. Moderate (57 [50–63 years 
old) and severe (66 [58.8–69.5] course-patients were significantly older 
than mild (48 [40–51.5]) course-patients (P = 0.0121, P = 0.0373 
respectively). Moderate course-patients were more likely to be smokers 
compared to mild course-patients (5/14 [35.7%] vs 0/19 [0%], 
P = 0.0253). 
3.3. MS characteristics 
There was differing prevalence of progressive phenotypes of MS 
among courses of COVID-19. Out of severe course 2/6 [33.3%] had 
PPMS and 0/6 [0%] had SPMS and out of the moderate course 1/14 
[7.14%] had PPMS and 5/14 [35.7%] had SPMS (1 patient had un-
known MS history). This is in comparison to out of mild course where 
0/19 [0%] had PPMS and only 1/19 [5.26%] had SPMS (P = 0.0075). 
Moderate course-patients had a significantly longer duration of MS than 
patients with mild, but not compared to those with severe courses(16 
[11.5–27] years vs 11 [6–14.5] years and 5 [3–10] years, P = 0.0480, 
P = 0.283).(Table 1a). 
EDSS was ≥6.0 in 1/19 (5.26%) with the mild course, significantly 
less than patients with moderate courses (9/15 [60%], P = 0.00435). 
This was also less than patients with severe course-patients, though not 
statistically significant (2/6 [33.3%], P = 0.200). More patients with 
moderate courses were residents of nursing homes compared to those 
with mild courses (7/15[46.7%] vs 0/19 [0%], P = 0.0036). 
3.4. DMT usage 
There was a relatively higher prevalence of DMT use in patients 
with mild and moderate courses compared to those with severe courses, 
although not found to be statistically significant across groups 
(mild:17/19[89.5%] and moderate:12/15[80%] vs. severe:3/6[50%], 
P = 0.123). Frequencies of different types of DMT appeared to be si-
milar across courses. (Table 2) 
3.5. Comorbidities 
There were more patients with moderate courses who had hy-
pertension compared to those with mild courses (10/15 [66.7%] vs 3/ 
19 [15.8%], P = 0.0127). There were more patients with severe courses 
who had diabetes compared to those with mild courses (4/6 [66.7%] vs 
1/19 [5.26%], P = 0.005).(Table 1b). 
3.6. Clinical course of infection 
Overall, initial presenting symptoms were similar among each 
course of COVID-19. All moderate and severe courses, as expected, had 
chest X-ray obtained compared to only 2/19 (10.5%) patients with mild 
courses (P = 0.0005). Patients with severe courses had quantifiably 
higher levels of lactate dehydrogenase (LDH, 598 [402–807] IU/L vs 
312 [245–394] IU/L, P = 0.0452).(Table 1c) Patients with moderate 
and severe courses were more likely to be treated for COVID-19 com-
pared to those with mild courses (12/15 [80%] and 5/6 [83.3%] vs4/ 
19 [21.1%], P = 0.00429, P = 0.0178).(Table 1d). 
All admitted patients were not given DMTs during admission (20/ 
20, 100%). Duration of COVID-19 symptoms was similar among all 
courses (P = 0.304). Patients with severe courses were more likely to 
be admitted longer compared to those with moderate courses (15.5 
[14.2–16.8] days vs 4 [4–9.5] days, P = 0.006). (Table 1e). 
Table 2 
Different types of DMTs frequency.       
DMT All Mild Moderate Severe  
None 8 2 3 3 
Alemtuzumab 1 1 0 0 
Dimethyl Fumarate 6 3 2 1 
Fingolimod 2 2 0 0 
Glatiramer acetate 3 1 2 0 
Interferon-beta 2 1 1 0 
IV Steroids 1 0 1 0 
Natalizumab 2 2 0 0 
Ocrelizumab 12 6 4 2 
Teriflunomide 3 1 2 0 
Table showing the frequency of different DMTs for each COVID 19 disease 
course.  
F. Chaudhry, et al.   Journal of the Neurological Sciences 418 (2020) 117147
3
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on December 16, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
4. Discussion 
4.1. MS characteristics and comorbidities associated with worse COVID-19 
course 
MS is a heterogeneous disease as PPMS and SPMS are associated 
with a later age of onset. Also since SPMS evolves from RRMS, these 
patients tend to be older with more disablities [10–12]. Older age, 
certain comorbidities and living in nursing homes are significant risk 
factors for COVID-19 [13]. Therefore, as expected, MS patients with 
moderate-severe courses were more likely to have PPMS and SPMS 
phenotypes, comorbidities (smoking, hypertension, and diabetes), and 
EDSS scores ≥6.0. These patients also tended to be older and frequently 
resided in nursing homes. 
4.2. DMT usage and infection risk 
It is known that certain DMTs have higher infectious risk compared 
to others; therefore, it has been a concern that cell depleting DMTs 
would be associated with higher COVID-19 risk [14]. Our cohort was 
not powered to detect differences in infectious outcomes based on type 
of DMT, however, it doesn't appear to be bias regarding certain DMTs in 
moderate-severe courses. In fact, it appears that more patients with 
moderate and severe courses were not on any DMT compared to those 
with mild courses. DMTs have been hypothesized to attenuate the cy-
tokine-storm response in COVID-19, though this is still purely spec-
ulative [14]. In fact, Louapre et al. found that there were higher pro-
portions of severe COVID-19 cases in MS patients that were not 
receiving DMTs [15]. Nonetheless, usage of DMTs do not necessarily 
appear to be associated with more severe COVID-19-courses. These 
findings correspond to those in ongoing North American COVID-19 MS 
survey database (covims.org) and Italian cohort surveyed by Sormani el 
al. where patients who died tended to be older, have PPMS or SPMS, 
and have significant disability and comorbidities, but were less likely to 
be on DMT [3,16]. 
4.3. Overall mortality of COVID-19 in MS 
As of 5/25/2020, the Detroit Health Department has reported a 
12.3% citywide COVID-19 mortality rate among laboratory confirmed 
cases [17]. Even though we had a small sample size, our MS cohort 
reported a similar mortality rate (10%) and was like that reported by 
Sormani et al. in confirmed-COVID-19 positive MS patients (5/57 
[8.78%]) [3]. Therefore, our mortality rate could possibly be consistent 
with a larger sample size and similar to that of the general population. 
What is unique to our cohort compared to the Italian cohort is that 
both Detroit and Chicago have large populations of African Americans 
who are believed to suffer from worse COVID-19 outcomes when 
compared to that seen in white Americans [18]. Our cohort did not 
show any statistically significant difference in terms of MS character-
istics and outcomes based on race, however it appears that patients 
with more severe courses tended to be African American. This may be 
due to significant socioeconomic disadvantages and higher prevalence 
of comorbidities (i.e hypertension, diabetes) among African Americans, 
however our cohort was small and more studies are required to in-
vestigate this racial disparity [19]. 
5. Limitations and conclusions 
A significant limitation to our study is the relatively small sample 
size collected; therefore risk-stratification adjusting for confounders 
was not possible. Larger studies are therefore required in order to 
correct for potential confounding variables. Also, there was a significant 
discrepancy in sample-size for each course, as there were only 6 
patients with severe disease course. Therefore, significant differences 
may not have been detected in post hoc comparisons and only very 
strong factors were found to be associated with disease outcomes. 
Regardless, we showed that certain MS-characteristics were more fre-
quent in those with more severe COVID-19 courses. 
Supplementary data to this article can be found online at https:// 
doi.org/10.1016/j.jns.2020.117147. 
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